Over the past several years, AstraZeneca has received multiple regulatory approvals from the European Medicines Agency (EMA) for the use of osimertinib, durvalumab, and tremelimumab in the treatment of lung cancer. These approvals span various disease stages and histological subtypes and have contributed to significant changes in treatment algorithms for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
